InsiderTrades.com logo
Christine Bellon net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Christine Bellon Biography and Net Worth

Chief Legal Officer of Beam Therapeutics

Dr. Christine Bellon is Chief Legal Officer of Beam Therapeutics. She brings to Beam more than 25 years of experience in the life science industry. Prior to joining Beam, she served as Senior Vice President, General Counsel and Corporate Secretary for Forma Therapeutics, where she built and led a legal team, negotiated changes to the company’s operating structure, and played a key role in negotiations with Forma’s strategic partner. Prior to Forma, Dr. Bellon was Senior Vice President of Legal Affairs for Relay Therapeutics, where she helped obtain foundational partnerships for the company and formulated its intellectual property strategy. Prior to Relay, she served as Vice President of Legal Affairs and Corporate Secretary at Blueprint Medicines, where she was instrumental in building its global IP portfolio, securing strategic partnerships and executing its initial public offering. Earlier in her career, Dr. Bellon practiced law and served in legal leadership roles at Hydra Biosciences and Infinity Pharmaceuticals.

Dr. Bellon holds a B.S. in Chemistry from Yale University; a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology, where she did research in the laboratory of K. Barry Sharpless; and a J.D. from Columbia Law School.

What is Christine Bellon's net worth?

The estimated net worth of Christine Bellon is at least $2.34 million as of January 2nd, 2025. Dr. Bellon owns 102,968 shares of Beam Therapeutics stock worth more than $2,339,330 as of March 25th. This net worth approximation does not reflect any other investments that Dr. Bellon may own. Additionally, Dr. Bellon receives a salary of $680,080.00 as Chief Legal Officer at Beam Therapeutics. Learn More about Christine Bellon's net worth.

How old is Christine Bellon?

Dr. Bellon is currently 58 years old. There are 4 older executives and no younger executives at Beam Therapeutics. The oldest executive at Beam Therapeutics is Dr. Amy Simon M.D., Chief Medical Officer, who is 60 years old. Learn More on Christine Bellon's age.

What is Christine Bellon's salary?

As the Chief Legal Officer of Beam Therapeutics Inc., Dr. Bellon earns $680,080.00 per year. There are 3 executives that earn more than Dr. Bellon. The highest earning executive at Beam Therapeutics is Mr. John M. Evans M.B.A., CEO & Director, who commands a salary of $1,130,000.00 per year. Learn More on Christine Bellon's salary.

How do I contact Christine Bellon?

The corporate mailing address for Dr. Bellon and other Beam Therapeutics executives is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. Beam Therapeutics can also be reached via phone at 857-327-8775 and via email at investors@beamtx.com. Learn More on Christine Bellon's contact information.

Has Christine Bellon been buying or selling shares of Beam Therapeutics?

Within the last three months, Christine Bellon has sold $30,627.88 in Beam Therapeutics stock. Most recently, Christine Bellon sold 1,241 shares of the business's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $24.68, for a transaction totalling $30,627.88. Following the completion of the sale, the insider now directly owns 102,968 shares of the company's stock, valued at $2,541,250.24. Learn More on Christine Bellon's trading history.

Who are Beam Therapeutics' active insiders?

Beam Therapeutics' insider roster includes Christine Bellon (Chief Legal Officer), Terry-Ann Burrell (CFO), Giuseppe Ciaramella (Insider), Graham Cooper (Director), John Evans (CEO), John Evans (CEO), and Amy Simon (Chief Medical Officer). Learn More on Beam Therapeutics' active insiders.

Are insiders buying or selling shares of Beam Therapeutics?

In the last twelve months, insiders at the sold shares 14 times. They sold a total of 349,876 shares worth more than $9,660,529.49. The most recent insider tranaction occured on January, 30th when CEO John M Evans sold 30,000 shares worth more than $802,500.00. Insiders at Beam Therapeutics own 4.2% of the company. Learn More about insider trades at Beam Therapeutics.

Information on this page was last updated on 1/30/2025.

Christine Bellon Insider Trading History at Beam Therapeutics

See Full Table

Christine Bellon Buying and Selling Activity at Beam Therapeutics

This chart shows Christine Bellon's buying and selling at Beam Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$31ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$40k-$20k$0$20k$40kTotal Insider BuyingTotal Insider Selling

Beam Therapeutics Company Overview

Beam Therapeutics logo
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $23.22
Low: $22.64
High: $24.05

50 Day Range

MA: $26.73
Low: $22.59
High: $34.16

2 Week Range

Now: $23.22
Low: $20.84
High: $35.25

Volume

2,393,968 shs

Average Volume

1,224,788 shs

Market Capitalization

$2.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.91